Skip to Content

Coronavirus information for Feinberg.

Download the full-sized PDF of Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways
Download the file

Actions

Download Analytics Citations

Export to: EndNote

Collections

This file is in the following collections:

COVID-19 Community

Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways Open Access (recommended)

Mazewski C, Perez RE, Fish EN, Platanias LC. Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. Frontiers in Immunology. 2020;11:13.

Descriptions

Resource type(s)
Review
Keyword
interferon
signaling
MAP kinase signaling
signal transducer and activator of transcription
mammalian target of rapamycin
mRNA translation
SARS-CoV-2
COVID-19
Rights
Attribution 4.0 International

Creator
Mazewski, Candice Elise
Perez, Ricardo Ernesto
Fish, Eleanor N.
Platanias, Leonidas C
Abstract
For several decades there has been accumulating evidence implicating type I interferons (IFNs) as key elements of the immune response. Therapeutic approaches incorporating different recombinant type I IFN proteins have been successfully employed to treat a diverse group of diseases with significant and positive outcomes. The biological activities of type I IFNs are consequences of signaling events occurring in the cytoplasm and nucleus of cells. Biochemical events involving JAK/STAT proteins that control transcriptional activation of IFN-stimulated genes (ISGs) were the first to be identified and are referred to as canonical signaling. Subsequent identification of JAK/STAT-independent signaling pathways, critical for ISG transcription and/or mRNA translation, are denoted as non-canonical or non-classical pathways. In this review, we summarize these signaling cascades and discuss recent developments in the field, specifically as they relate to the biological and clinical implications of engagement of both canonical and non-canonical pathways.
Related URL
Publisher
FRONTIERS MEDIA SA
Date Created
2020-11-23
Original Identifier
(PMID) 33329603
Grants and funding
NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA77816, CA121192]; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32 CA070085]
DOI
10.3389/fimmu.2020.606456

File Details

File Properties
Mime type: application/pdf
File size: 1050.8 kB